For more than a decade, Brazil's Butantan Institute has been pursuing a vaccine capable of protecting anyone — the previously infected and the never-exposed alike — against all four strains of dengue. In December 2022, that work reached a quiet but significant threshold: preliminary Phase III trial data, drawn from 17,000 volunteers, was delivered to the national health regulator Anvisa. The full submission is not expected until mid-2024, but the urgency behind it is already written in the numbers — 978 Brazilians died from dengue in 2022, the highest toll in seven years.
Olhar Digital
· Dec 15, 2022
· health
· 2 min de leitura
High
Apuração: Verificado
Butantan submits dengue vaccine preliminary data to Brazil's health regulator
Brazil recorded 978 dengue-related deaths in 2022, the highest annual toll since 2015, demonstrating significant public health burden.
◉
Health & Medicine
2834 artigos relacionados
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% correspondência
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% correspondência
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% correspondência
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% correspondência
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% correspondência
Cobertura Relacionada
Folha de S.Paulo · Aug 26
Ônibus escolar cai em ribanceira e deixa duas crianças feridas em SC
Ônibus escolar com dez crianças caiu dez metros em ribanceira em Santa Catarina. Duas crianças ficaram feridas e foram h…
G1 · Aug 26 Incêndio em hospital do Paquistão mata ao menos 15 bebêsPelo menos 15 recém-nascidos morreram em incêndio no hospital PIMS em Islamabad, causado por falha no sistema de ar-cond…
G1 · Aug 26 Zelador agredido com paulada evolui na UTI, mas segue internado no DFZelador agredido há 15 dias por homem em situação de rua apresenta melhora clínica na UTI, respondendo a estímulos e com…
Google News · Aug 26 Diretor do Atlético-MG acusa Kaio Jorge de 'maldade e deslealdade' após lance polêmicoDirigente do Atlético-MG acusa Kaio Jorge de jogada maldosa e desleal que resultou em queda do zagueiro Ruan Tressoldi, …
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
🌎
Brazil's Butantan Institute advances indigenous dengue vaccine development, potentially reducing dependence on foreign pharmaceutical suppliers and strengthening regional health sovereignty in Latin America.
Escalation Risk
low
Confidence
HIGH
Brazil
Latin America
Global pharmaceutical market
Brazil seeks to establish domestic vaccine production capacity, reducing reliance on Sanofi's Dengvaxia and enhancing technological sovereignty. Success would strengthen Brazil's position as a regional biotech leader and increase leverage in global health negotiations.
Similar to India's vaccine development programs that reduced dependency on Western pharmaceutical monopolies and positioned the nation as a generic drug powerhouse, Brazil aims to democratize dengue vaccine access across Latin America.
Lente Econômica
📈
Brazil's Butantan Institute advances dengue vaccine development with Phase III trials showing 100% antibody production, potentially creating a competitive public health alternative to Sanofi's private-sector Dengvaxia vaccine.
Market Signal
mixed
Confidence
MED
Pharmaceutical and biotechnology
Public health and healthcare services
Medical devices and diagnostics
Insurance and healthcare financing
Potential future access to a publicly-funded dengue vaccine could reduce out-of-pocket healthcare costs for Brazilian consumers, particularly lower-income populations currently unable to afford Dengvaxia. However, benefits remain contingent on regulatory approval and public distribution timelines extending into 2024-2025.
Successful approval would strengthen Brazil's domestic pharmaceutical capacity and reduce dependence on imported vaccines. May prompt regulatory harmonization discussions and could influence pricing dynamics in the dengue vaccine market. Public sector vaccine availability may reduce pressure on private healthcare spending and improve epidemiological control in endemic regions.